FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/12/2025
Back to search
Official data from USPTO
DEVELOPICK
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
DEVELOPICK
ST13
US500000079365404Class
40, 42
Filing
79365404
Registration
7539787
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
04/13/2025
Classification
Registered
Trademark type
Word
Nice classes
40, 42
Filing date
01/31/2023
Registration date
10/22/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/22/2024
Last transaction
04/13/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
KR
Examiner
BLAZICH,JOAN MICHELE
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Samsung Biologics Co., Ltd.
Representatives
Brian P. Gregg McNees Wallace & Nurick
Technical classification
Nice Classes
Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 40
Custom manufacture of polyclonal antibodies for pharmaceutical use; custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; processing of plant hormones being phytohormones; processing of medicinal materials; processing of pharmaceutical preparations; custom manufacture of pharmaceuticals; processing of pharmaceuticals; custom manufacture of pharmaceutical bispecific antibodies; processing of chemical reagents
Class 42
Advisory services relating to technological research in the field of pharmaceutical manufacturing processes; advisory services relating to scientific analysis in the field of nucleic acids; research relating to sciencescientific research; conducting of technical feasibility studiesconducting of feasibility studies in the field of new technologies; multiple nucleic acid scientific analysis; multiple nucleic checkmaterials testing; analysis of materials; materials testing and evaluation; chemical analysis services for use in the testing of material; molecular analysisscientific analysis in the field of molecular biology; advisory services relating to biotechnology; technical management advisory services relating to biotechnologyscientific research consultingbiotechnology consultancy services; biochemical analysis; advisory services relating to biochemistry research; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; design of new products for others; technical advice relating to safetyconsumer product safety testing consultation; pharmaceutical research and development; pharmaceutical products evaluation; clinical research in the field of medicines; services for assessing the efficiency of pharmaceuticalstesting of pharmaceuticals; testing of raw materials; fusion protein analysis being testing of raw materials; computer programming services in the medical field; computer project management services relating to imaging medical data; medicine research being medical research; scientific analysis and quality evaluation of medical product development; pharmaceutical technology advisory servicecomputer technology consultancy; pharmaceutical product evaluation; providing scientific and medical information on the testinginspection and research of medical products; pharmaceutical product evaluation; scientific laboratory services relating to the production of bispecific antibody; bispecific antibody drug development; double antibody reagent scientific research and development; evaluating of clinical trial progressconducting clinical trials for others; clinical researchconducting clinical trials for others; evaluation of product development being product quality evaluation; product safety testing; quality assurance consultancy in the field of pharmaceuticals; quality assessment being product testing; scientific research advisory services relating to chemical reagents; evaluation of chemical syntheses being product quality evaluation
Publications
History of USPTO decisions and trademark events.
29 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/25/2025
FIMP
FINAL DISPOSITION PROCESSED
03/25/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/22/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/22/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
10/22/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/31/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/14/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
08/14/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/06/2024
PUBO
PUBLISHED FOR OPPOSITION
08/06/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/17/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/01/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/14/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/14/2024
ALIE
ASSIGNED TO LIE
06/14/2024
NREV
NOTICE OF REVIVAL - E-MAILED
05/14/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/14/2024
PETG
PETITION TO REVIVE-GRANTED
05/14/2024
PROA
TEAS PETITION TO REVIVE RECEIVED
05/14/2024
RFNP
REFUSAL PROCESSED BY IB
11/22/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/02/2023
RFRR
REFUSAL PROCESSED BY MPU
11/02/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/02/2023
CNRT
NON-FINAL ACTION WRITTEN
11/01/2023
DOCK
ASSIGNED TO EXAMINER
10/30/2023
MAFR
APPLICATION FILING RECEIPT MAILED
03/21/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/17/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/16/2023
Continuous trademark protection
Get notified about every new filing that threatens DEVELOPICK or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.